ClinicalTrials.gg

Drug

Human Growth Hormone clinical trials

Also written Somatropin, Genotropin, Saizen and LY137998.

studies test it
210
open now
12
in phase 3
85
first study started
1990

Keep track of what changes. Save the Human Growth Hormone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

203 studies that test it; most in 2005 (20); 1 more planned to start later

Studies that test Human Growth Hormone, by start year
YearStudies
19903
19911
19921
19932
19963
19974
19984
19995
20007
20016
20028
200313
200414
200520
200612
20077
200813
20094
20109
20116
20123
20135
20148
20157
20163
20175
20186
20195
20202
20222
20235
20242
20254
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
28
Phase 2
51
Phase 3
85
Phase 4
44
No phase
19

What it is tested for

Each study’s main condition, where its own words name it.

Who runs them

Industry 113 · Other 97

Novo Nordisk A/S (34) · Changchun GeneScience Pharmaceutical Co., Ltd. (19) · Pfizer (16) · Merck KGaA, Darmstadt, Germany (11) · Eli Lilly and Company (9) · EMD Serono (8) · University of Aarhus (8) · Massachusetts General Hospital (6)

Often tested with

Tested in the same studies.

Testosterone (3) · Pegvisomant (3) · Insulin, Regular, Human (2) · Octreotide (2) · Glucagon (2) · Glucose (2) · Testosterone enanthate (2) · Propranolol (2)

Studies

Open first, then newest update. How each study uses Human Growth Hormone is read from its arms, and is right about nine times in ten.

Testing it · 210

See all 210 studies that test Human Growth Hormone →

Given in every arm · 5 — Human Growth Hormone is usual care beside what is tested
As the comparator · 36 — what is tested is compared with Human Growth Hormone

Showing 20 of 36.

Codes

What other systems call Human Growth Hormone · ClinicalTrials.gg INT008700

  • RxNorm 61148One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.